Moore Capital Management, LP Bellus Health Inc. Transaction History

Moore Capital Management, LP

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$8.22 - $10.76 $1.67 Million - $2.18 Million	-202,764 Reduced 48.29%	217,138 $1.78 Million
Q3 2022 Nov 14, 2022	BUY	$8.95 - $12.0 $2.73 Million - $3.66 Million	305,188 Added 266.04%	419,902 $4.43 Million
Q2 2022 Aug 15, 2022	BUY	$6.46 - $10.02 $741,052 - $1.15 Million	114,714 New	114,714 $1.06 Million

128K

Ticker BLU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,793,000
Description
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. Th...

Get notified when there are updates to the investment portfolio of Moore Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Moore Capital Management, LP with notifications on news.